Immuncheckpoint Inhibitors: Current Indications and Possible Future Concepts

Deutsche medizinische Wochenschrift
Max SchlaakSebastian Theurich

Abstract

Immuno-oncological therapy concepts have already achieved great success in the treatment of a number of advanced malignancies, thereby rapidly gaining access to clinical practice. Immuncheckpoint inhibitors are also being reviewed in the adjuvant setting. In malignant melanoma, they have already shown efficacy. Different combination strategies of Immuncheckpoint inhibitors are currently undergoing clinical evaluation to further improve treatment outcomes. However, this has so far also been associated with a significantly increased immune-mediated rate of side effects. Effective and safe immuno-oncology requires good clinical management of immune-mediated side effects. Radiological assessment is challenging under immunotherapy and requires new standards (iRECIST). Encouraging is the fact that immunotherapy also causes long-term remissions in some of the patients. This raises the hope for a fundamentally curative potential of immuno-oncological therapeutic approaches.

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Deutsche medizinische Wochenschrift
Alexander Shimabukuro-VornhagenMichael von Bergwelt-Baildon
Nature Reviews. Clinical Oncology
Alexander M M Eggermont, Caroline Robert
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Sophia M WildenStephan Grabbe
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Scott J AntoniaPaolo A Ascierto
© 2022 Meta ULC. All rights reserved